Articles tagged with Metastasis
Comprehensive exploration of living organisms, biological systems, and life processes across all scales from molecules to ecosystems. Encompasses cutting-edge research in biology, genetics, molecular biology, ecology, biochemistry, microbiology, botany, zoology, evolutionary biology, genomics, and biotechnology. Investigates cellular mechanisms, organism development, genetic inheritance, biodiversity conservation, metabolic processes, protein synthesis, DNA sequencing, CRISPR gene editing, stem cell research, and the fundamental principles governing all forms of life on Earth.
Comprehensive medical research, clinical studies, and healthcare sciences focused on disease prevention, diagnosis, and treatment. Encompasses clinical medicine, public health, pharmacology, epidemiology, medical specialties, disease mechanisms, therapeutic interventions, healthcare innovation, precision medicine, telemedicine, medical devices, drug development, clinical trials, patient care, mental health, nutrition science, health policy, and the application of medical science to improve human health, wellbeing, and quality of life across diverse populations.
Comprehensive investigation of human society, behavior, relationships, and social structures through systematic research and analysis. Encompasses psychology, sociology, anthropology, economics, political science, linguistics, education, demography, communications, and social research methodologies. Examines human cognition, social interactions, cultural phenomena, economic systems, political institutions, language and communication, educational processes, population dynamics, and the complex social, cultural, economic, and political forces shaping human societies, communities, and civilizations throughout history and across the contemporary world.
Fundamental study of the non-living natural world, matter, energy, and physical phenomena governing the universe. Encompasses physics, chemistry, earth sciences, atmospheric sciences, oceanography, materials science, and the investigation of physical laws, chemical reactions, geological processes, climate systems, and planetary dynamics. Explores everything from subatomic particles and quantum mechanics to planetary systems and cosmic phenomena, including energy transformations, molecular interactions, elemental properties, weather patterns, tectonic activity, and the fundamental forces and principles underlying the physical nature of reality.
Practical application of scientific knowledge and engineering principles to solve real-world problems and develop innovative technologies. Encompasses all engineering disciplines, technology development, computer science, artificial intelligence, environmental sciences, agriculture, materials applications, energy systems, and industrial innovation. Bridges theoretical research with tangible solutions for infrastructure, manufacturing, computing, communications, transportation, construction, sustainable development, and emerging technologies that advance human capabilities, improve quality of life, and address societal challenges through scientific innovation and technological progress.
Study of the practice, culture, infrastructure, and social dimensions of science itself. Addresses how science is conducted, organized, communicated, and integrated into society. Encompasses research funding mechanisms, scientific publishing systems, peer review processes, academic ethics, science policy, research institutions, scientific collaboration networks, science education, career development, research programs, scientific methods, science communication, and the sociology of scientific discovery. Examines the human, institutional, and cultural aspects of scientific enterprise, knowledge production, and the translation of research into societal benefit.
Comprehensive study of the universe beyond Earth, encompassing celestial objects, cosmic phenomena, and space exploration. Includes astronomy, astrophysics, planetary science, cosmology, space physics, astrobiology, and space technology. Investigates stars, galaxies, planets, moons, asteroids, comets, black holes, nebulae, exoplanets, dark matter, dark energy, cosmic microwave background, stellar evolution, planetary formation, space weather, solar system dynamics, the search for extraterrestrial life, and humanity's efforts to explore, understand, and unlock the mysteries of the cosmos through observation, theory, and space missions.
Comprehensive examination of tools, techniques, methodologies, and approaches used across scientific disciplines to conduct research, collect data, and analyze results. Encompasses experimental procedures, analytical methods, measurement techniques, instrumentation, imaging technologies, spectroscopic methods, laboratory protocols, observational studies, statistical analysis, computational methods, data visualization, quality control, and methodological innovations. Addresses the practical techniques and theoretical frameworks enabling scientists to investigate phenomena, test hypotheses, gather evidence, ensure reproducibility, and generate reliable knowledge through systematic, rigorous investigation across all areas of scientific inquiry.
Study of abstract structures, patterns, quantities, relationships, and logical reasoning through pure and applied mathematical disciplines. Encompasses algebra, calculus, geometry, topology, number theory, analysis, discrete mathematics, mathematical logic, set theory, probability, statistics, and computational mathematics. Investigates mathematical structures, theorems, proofs, algorithms, functions, equations, and the rigorous logical frameworks underlying quantitative reasoning. Provides the foundational language and tools for all scientific fields, enabling precise description of natural phenomena, modeling of complex systems, and the development of technologies across physics, engineering, computer science, economics, and all quantitative sciences.
Researchers have identified a 177-gene signature common to metastasis across cancers, allowing for personalized risk assessment and potential therapies. The discovery could lead to broader treatment options, faster drug access, and improved patient outcomes.
Scientists cultivate stable tumor organoids directly from blood samples of breast cancer patients, revealing a molecular signaling pathway that ensures cancer cell survival and resistance to therapy. The team develops an approach to specifically eliminate these tumor cells in lab experiments.
The study identified a modified imaging approach and volumetric measurements as more accurate in predicting survival compared to other methods. These approaches worked well even for small tumors, suggesting they should be included in future studies.
A new study found that nearly half of high-risk prostate cancer patients have metastatic disease when evaluated with advanced PSMA-PET imaging, suggesting traditional imaging may underestimate cancer spread. This challenge the interpretation of previous studies like EMBARK trial, and support the inclusion of PSMA-PET for patient select...
A new experimental technique has developed a molecular flashlight to monitor molecular changes in the brain caused by cancer and other neurological pathologies. The technique uses vibrational spectroscopy to illuminate nerve tissue, allowing for the analysis of molecular changes caused by tumours or injuries.
Researchers developed biodegradable polymeric nanoparticles that selectively target cancer cells with two approved drug pairs for skin and breast cancers. The treatment showed significantly enhanced therapeutic effects, reduced tumor size, and prolonged median survival in mice.
Researchers at MD Anderson Cancer Center have made significant breakthroughs in smoking cessation treatments, with a study finding that varenicline plus counseling is the most effective treatment for individuals with major depressive disorder. Additionally, a new radiotherapy technique demonstrates effectiveness in treating metastatic ...
The PATINA study demonstrates that palbociclib improves progression-free survival (PFS) in patients with HR+, HER2+ metastatic breast cancer, with a median PFS of 44.3 months. This represents an extension in median PFS of over 15 months compared to anti-HER2 therapy and endocrine therapy alone.
The study found a significant increase in late-stage breast cancer diagnoses among U.S. women, with annual percentage increases of up to 2.9% between 2004 and 2021. The researchers attribute the trend to factors such as lack of national screening programs, inconsistent guidelines, and increasing obesity rates.
A study published in Cell found a common variant of the PCSK9 gene increases the risk of breast cancer metastasis by 22% compared to those without it. Researchers propose using an antibody targeting PCSK9 to suppress this variant and reduce metastatic disease.
A study led by UF Health Cancer Center researchers found that a toxin in the bacteria Campylobacter jejuni accelerates the spread of colorectal tumors. The findings could lead to new tools for detecting metastatic colorectal cancer early, ultimately helping determine patients who need more aggressive treatments.
Researchers found that tumor cell secreted DNA in extracellular vesicles acts as a 'danger' signal to activate an anti-tumor response in the liver, reducing liver metastasis risk. The discovery improves understanding of cancer progression and anticancer immunity.
A study found that postmenopausal women with low-risk tumors experience a long-term benefit from anti-hormonal treatment of at least 20 years, while younger women do not. The researchers highlight the need for new markers to predict long-term risk and benefit in younger patients.
A groundbreaking study explores the therapeutic potential of tumor-infiltrating lymphocytes (TILs) derived from metastatic lymph nodes in advanced cervical cancer. The innovative approach demonstrates a manageable safety profile, while also showing promise for improving treatment efficacy.
Researchers studied ovarian cancer cell migration patterns on soft and stiff surfaces, finding that epithelioid cells are more migratory than mesenchymal cells on stiffer matrices. The study used a novel software toolkit to analyze cell behavior over time, revealing a unique 'slip' movement pattern in epithelioid cells.
Researchers at The Wistar Institute have discovered a new combination therapy approach that shrinks tumors and improves survival rates in metastatic ovarian cancer. By activating myeloid cells, the treatment overcomes immunosuppression around tumors and makes them more receptive to chemotherapy.
Epigenetic changes, driven by oxidative stress, facilitate tumor metastasis through EMT, ECM remodeling, and CTCs survival. Novel therapeutic strategies combining oxidative stress modulators and epigenetic drugs show promise in combating metastasis.
Researchers have discovered a new strategy to overcome docetaxel resistance in advanced prostate cancer patients, which may improve the efficacy of chemotherapy and prolong overall survival. The approach involves inhibiting cholesterol and lipid biosynthesis, reinducing sensitivity to the drug docetaxel.
The Wyss Institute's iNodes team has been awarded an ARPA-H Sprint for Women's Health to develop implantable immune organs for treating ovarian cancer. The iNodes concept is based on the formation of lymphoid organs in tumors, which can be reprogrammed to attack cancer cells and retain a long-term immune memory.
Researchers at UCLA Health Jonsson Comprehensive Cancer Center have shown that combining pembrolizumab, an immunotherapy drug, with standard chemotherapy can improve treatment outcomes for patients with advanced small cell bladder cancer and small cell/neuroendocrine prostate cancer. The study found that the combination treatment resul...
A collaborative study led by Dr. Julie St-Pierre at the University of Ottawa found that promoting mitochondrial elongation in cancer cells hobbles their ability to metastasize. The research team identified a common signature that could help determine which pathways lead to decreased metastasis.
Researchers document remarkable response to pembrolizumab in patient with metastatic adenosquamous pancreatic cancer (ASCP) and KRAS G12C mutation. The study highlights potential shift in treatment of ASCP, a rare form of pancreatic cancer traditionally underserved by current therapies.
A new MSK study has identified patterns in how cancer cells reprogram themselves during metastasis, providing new details on cellular plasticity. The research team compared samples from patients with advanced colorectal cancer and found clear patterns in the way metastatic cells change their identity to access early cell states.
A remarkable clinical and metabolic response is reported in a metastatic BRAF V600E-mutated glomangiosarcoma treated with encorafenib and binimetinib. The combination of BRAF and MEK inhibitors achieves a long-lasting complete morpho-metabolic response in the patient.
Researchers developed a method to assess which patients with metastatic triple-negative breast cancer can benefit from immunotherapy. The tool uses predictive biomarkers and machine learning-based approaches to identify patients who are likely to respond to treatment.
TYRA-300 shows promise in treating metastatic bladder cancer patients with FGFR3 gene mutations, achieving a 50% overall response rate and 100% disease control rate. The treatment also displays improved tolerability with lower side effects compared to existing pan-FGFR inhibitors.
Researchers created a 3D-printed model to mimic the conditions that spur cancer cells' spread, allowing them to visualize this process in real-time. The model revealed a mechanism where low oxygen levels promote metastasis through lowering pH levels.
Researchers at Weill Cornell Medicine identified a unique enzyme called FTSJ1 that enables melanoma cells to escape oxidative stress and spread. By targeting this enzyme, therapies may prevent or treat metastasis with minimal side effects.
Researchers found that physically fitter patients with metastatic lung cancer live longer and respond better to chemotherapy. The study identified biomarkers in blood plasma that can indicate which patients are most likely to respond to treatment.
Researchers reported a complete and long-lasting response to immunotherapy in a stage IV non-small cell lung cancer patient with brain metastases. The patient achieved overall survival of 87 months and progression-free survival of 73 months after treatment sequencing.
Researchers develop physiologically relevant model to investigate breast cancer bone metastasis, holding promise for predicting risk and developing new treatments.
Researchers found that ApoE protects melanoma cells from ferroptosis by increasing antioxidant capacity and neutralizing lipids. This discovery highlights the APOE gene as a critical factor in melanoma cell survival, potentially opening new avenues for treatment.
Researchers have engineered probiotic bacteria to educate the immune system to destroy cancer cells, opening the door for a new class of cancer vaccines. The bacterial vaccine proved more efficacious than peptide-based therapeutic cancer vaccines in studies using mouse models of advanced colorectal and melanoma cancers.
Research highlights molecular chaperones' role in maintaining tumor suppressor stability and functional integrity. This understanding is crucial for developing targeted therapies for multiple cancers.
A recent study published in Nature Cancer has discovered that cancer cells exhibit opposing pro and antitumor programs, with the former promoting metastasis and the latter combating tumor growth. This finding opens new avenues for therapeutic strategies to target highly aggressive and therapy-resistant tumors.
Researchers at the Hebrew University of Jerusalem have developed a highly selective inhibitor for Matrix Metallopeptidase 7 (MMP7), an enzyme crucial for cancer spread and progression. The novel peptide D'20 demonstrates remarkable stability and selectivity, targeting MMP7 while leaving similar enzymes unaffected.
Researchers at Johns Hopkins Medicine developed a potential novel treatment for breast cancer bone metastasis using RK-33, which targets and inhibits the protein DDX3. The drug successfully eliminated breast cancer bone metastases in lab models by controlling cancer cell growth and proliferation.
A research team at IIT has identified a molecular signature in triple-negative breast cancer cells that can predict the formation of metastases and chemotherapy resistance. The study used single-cell sequencing to track the evolution of cancer cells over time, revealing key epigenetic features involved in tumor development.
Researchers at Montefiore Einstein Comprehensive Cancer Center have discovered a natural immune mechanism in mice that stops escaped cancer cells from developing into tumors elsewhere in the body. Alveolar macrophages recognize and interact with disseminated cancer cells, producing signals that keep them dormant.
A non-invasive blood test measuring circulating tumor cells can predict treatment response, disease progression, and overall survival in men with metastatic prostate cancer. Patients with more CTCs had shorter median survival lengths and a greater risk of death.
Researchers identified AM-101 as a potential new way to enhance radiation therapy for patients with lung cancer that has spread to the brain. The drug's ability to activate GABA(A) receptors increases autophagy in lung cancer cells, making them more sensitive to radiation treatment.
Researchers at CNIO propose a new treatment for brain metastasis by targeting pro-tumour astrocytes with immunotherapy. They identified TIMP1 as a biomarker to predict when immunotherapy is effective, and a clinical trial is underway to test the therapeutic efficacy of silibinin inhibition.
Two UCF cancer researchers, Alicja Copik and Debbie Altomare, have received $100,000 grants from the Florida Breast Cancer Foundation to develop new treatments for breast cancer. They focus on enhancing natural killer cells to fight cancer and harnessing the body's immune system to create new therapies.
Researchers propose reevaluating nomenclature for low-grade prostate cancer, a condition that rarely metastasizes or causes symptoms. This shift aims to balance detection with treatment to reduce harms of overdiagnosis and overtreatment.
A pooled analysis of three large, phase III clinical trials found that more than 40% of brain metastases patients can fully reverse cognitive losses with conformal radiation techniques. Recovery was more likely for those treated with highly targeted radiation compared to standard whole-brain treatment.
Researchers at Cold Spring Harbor Laboratory create a roadmap of how prostate cancer spreads throughout the body, showing that aggressive cells seed cancer's rare migrations to bones, liver, lungs, and lymph nodes. The new technology offers a clearer picture of cancer spread and could lead to more targeted therapeutics.
The CheckMate 067 trial showed that combining nivolumab and ipilimumab improved outcomes for metastatic melanoma patients, with a median survival time over six years. Long-term follow-up found no new safety signals for the treatment, and metastatic melanoma survivors become increasingly likely to die of other causes as they age.
A drug that delivers chemotherapy directly to tumors has shown substantial and durable activity in treating brain metastases of HER2-positive breast cancer. The treatment, trastuzumab deruxtecan, has improved progression-free survival and objective response rates in patients with advanced disease.
A groundbreaking study has provided novel insights into the molecular underpinnings of gastric cancer peritoneal spread, paving the way for more effective treatments. The research also demonstrated the safety and potential efficacy of a new treatment approach in a clinical trial.
A new study published in Cell found that TGF-beta and RAS signaling pathways are both required for lung cancer metastasis. Inhibiting RREB1, a transcription factor controlled by RAS, disabled the metastatic process in mouse models, suggesting it could be a potential new drug target.
Researchers have developed a nanodrug that targets miR-10b, a small noncoding RNA implicated in cancer cell invasion and proliferation. The study shows that inhibiting miR-10b reduces the stemness of breast cancer cells, supporting dedifferentiation as a potential therapeutic mechanism.
Researchers have found that natural killer cells instinctively recognize and attack the XPO1 protein, which drives cancer growth. By targeting this protein, scientists may be able to activate more killer cells to destroy cancer cells. The study suggests that this approach could lead to personalized cancer treatment with less side effects.
Researchers create superhydrophobic array device (SHArD) mimicking the lotus leaf surface structure, enabling high-throughput generation of three-dimensional nanoscale tumor models. This platform helps study metastasis and primary tumors, shedding light on cancer progression.
A new treatment approach has been confirmed effective in a major study, showing that locally advanced rectal cancer patients can experience complete tumour disappearance without needing surgery. This method reduces the risk of recurrence and preserves normal bowel function, offering a promising alternative to traditional treatments.
A pivotal study supports belzutifan approval for patients with advanced kidney cancer, with belzutifan demonstrating a 25% lower risk of progression compared to everolimus. The HIF-2 inhibitor offers a novel therapeutic mechanism in advanced renal cell carcinoma treatment.
A new study published in Nature Medicine shows that precision therapy can improve survival for men with metastatic castration-resistant prostate cancer. The treatment, which involves analyzing the genetic profile of the tumor, has been shown to be more effective than chemotherapy in patients whose tumors have specific mutations.
Researchers developed a nanobody that targets V-ATPase c subunit and inhibits tumor cell invasion and metastasis. The nanobody was tested on 4T1-12B mouse breast cancer cells implanted in mice, where it showed effectiveness in preventing lung metastasis.
Researchers identified various CAF subsets that interact with the tumor microenvironment, promoting cancer spread. Targeting these specific subsets offers new therapeutic strategies to inhibit metastasis and improve patient outcomes.
A trial at UT Health San Antonio found that Sacituzumab Govitecan was well-tolerated and showed signs of effectiveness for patients with breast cancer who had progressed to brain tumors. The drug has been shown to deliver a topoisomerase inhibitor into tumors, providing promising clinical signals of efficacy.
Researchers found that sensory neurons secrete a neuropeptide driving cancer growth and spread through a previously unknown neuro-cancer crosstalk. An FDA-approved drug may prevent metastasis in breast cancer instances. The study suggests targeting this pathway to stop breast cancer progression.